Chemours Tidigare resultatutveckling
Tidigare kriterier kontrolleras 0/6
Chemours s intäkter har minskat med en genomsnittlig årlig takt på -55.7%, medan Chemicals -branschen såg intäkter på sjunkande 3.8% årligen. Intäkterna har varit fallande med en genomsnittlig takt på 1.5% per år.
Viktig information
-55.72%
Tillväxttakt i vinsten
-55.20%
Tillväxttakt för EPS
| Chemicals Tillväxt i branschen | 12.93% |
| Intäkternas tillväxttakt | -1.50% |
| Avkastning på eget kapital | -189.81% |
| Nettomarginal | -7.04% |
| Senaste uppdateringen av resultatet | 31 Mar 2026 |
Senaste uppdateringar av tidigare prestationer
Recent updates
Analysartikel • May 08
The Chemours Company Just Missed Earnings With A Surprise Loss - Here Are Analysts Latest Forecasts
It's been a mediocre week for The Chemours Company ( NYSE:CC ) shareholders, with the stock dropping 17% to US$22.41 in...Seeking Alpha • May 04
Chemours: Thesis Materialization In 2026 (Rating Downgrade)
Summary Chemours Company has delivered a 120%+ RoR in under six months, driven by strong refrigerant segment growth, especially Opteon adoption. Despite recent outperformance, CC now trades above my fair value target ($30/share), prompting a shift to a 'HOLD/Neutral' rating and portfolio rotation. CC remains fundamentally sound but faces persistent risks: high leverage ($3.5B net debt), regulatory liabilities, and cyclical end-market exposure, especially in TiO2. Future upside hinges on continued refrigerant growth, cost reductions, and deleveraging; current valuation reflects excessive optimism relative to near-term fundamentals. Read the full article on Seeking Alpha
Analysuppdatering • Apr 22
CC: Cooling Partnership And 2026 Outlook Will Support Further Earnings Upside
Analysts now cite slightly higher long term revenue growth, profit margin, and P/E assumptions as reasons for raising Chemours fair value estimate from $25.00 to $29.00 per share. What's in the News Chemours and 2CRSi entered a Joint Development Agreement following the qualification of Chemours' Opteon two phase immersion cooling fluid in current generation 2CRSi servers, aimed at advancing two phase cooling technologies for high density IT infrastructure and AI workloads (Key Developments).Analysuppdatering • Apr 08
CC: Share Repurchases And 2026 Outlook Will Support Earnings Upside
Analysts have raised their Chemours price target from $21.00 to $25.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple as key drivers of the change. What's in the News Chemours completed its share repurchase program announced on May 2, 2022, buying back 10,342,722 shares (6.76%) for a total of $309.28 million, with no additional shares repurchased between October 1, 2025 and December 31, 2025 (Key Developments).
Analysuppdatering • Mar 24
CC: PFAS Litigation Will Drive Cautious Outlook Despite Cooling Technology Partnership
Analysts have maintained their $17.00 price target for Chemours, citing updated assumptions that include a 10.25% discount rate, 3.37% revenue growth, a 13.84% profit margin, and a future P/E of 3.87x, which they state continue to support the prior fair value view. What's in the News Chemours reported that between October 1, 2025 and December 31, 2025, it repurchased 0 shares for US$0 under its existing program and indicated that it has completed the buyback of 10,342,722 shares, or 6.76%, for US$309.28 million under the authorization announced on May 2, 2022 (Key Developments).Analysuppdatering • Mar 09
CC: PFAS Legal Overhang And Cooling Partnership Will Shape Balanced Return Outlook
Analysts have raised their price target on Chemours from $13.00 to $17.00, citing updated assumptions around discount rate, revenue growth, profit margins, and future P/E that change their view of the company’s risk and earnings potential. What's in the News Chemours and 2CRSi entered a Joint Development Agreement after Chemours' Opteon two phase immersion cooling fluid was qualified in current generation 2CRSi servers, with a focus on advanced cooling for high density IT, AI, and next generation chips, and an emphasis on end user and environmental benefits.Analysuppdatering • Feb 22
CC: Earnings Outlook And PFAS Legal Overhang Will Shape Future Upside
Analysts have revised their Chemours price target from $18.00 to $21.00, citing updated assumptions around discount rate, revenue growth, profit margin and future P/E that slightly adjust the risk and earnings profile they are using in their models. What's in the News Chemours issued new Full Year 2026 earnings guidance, with management indicating an expectation for Net Sales growth in the 3% to 5% range.Analysuppdatering • Feb 08
CC: PFAS Class Action Risk Will Limit Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at $13.00, with the latest price target grounded in unchanged fair value assumptions, along with updated views on discount rate, revenue growth, profit margin and future P/E levels. What's in the News On January 6, 2026, a Montana federal judge denied motions to dismiss a class action against DuPont/Chemours, 3M and several other gear and materials manufacturers related to alleged toxic PFAS chemicals in firefighter turnout gear.Analysartikel • Feb 03
The Chemours Company (NYSE:CC) Shares Fly 27% But Investors Aren't Buying For Growth
The The Chemours Company ( NYSE:CC ) share price has done very well over the last month, posting an excellent gain of...
Analysuppdatering • Jan 25
CC: Legal Overhang And Margin Reset Will Shape Balanced Outlook
Analysts have trimmed their price target on Chemours to about US$16 from roughly US$18, pointing to adjustments in profit margin expectations and valuation multiples, even though assumptions for revenue growth and future P/E have shifted. What's in the News A Montana federal judge denied motions to dismiss a class-action lawsuit involving PFAS in firefighter turnout gear, allowing claims against DuPont/Chemours and other manufacturers to move forward, including Racketeer Influenced Corrupt Organizations (RICO) claims that will remain active pending a related Ninth Circuit decision (Lawsuits & Legal Issues).Analysuppdatering • Jan 11
CC: PFAS Lawsuit And Weaker Margins Will Restrain Future Shareholder Returns
Analysts have kept their Chemours fair value estimate steady at US$13.00. The latest price target update reflects adjusted assumptions around discount rate, revenue growth, profit margin and future P/E rather than a change in headline valuation.Analysuppdatering • Dec 26
CC: Future Profitability Challenges Will Temper Benefits Of Completed Share Buybacks
Analysts have modestly raised their price target on Chemours to 13.00 dollars, reflecting slightly stronger revenue growth expectations and higher assumed future valuation multiples, while this is partially offset by a more cautious view on long term profitability and risk. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Analysuppdatering • Dec 12
CC: Long-Term Margin Outlook Will Offset Near-Term Losses And Completed Buybacks
Analysts have raised their price target on Chemours from 11 dollars and 41 cents to 13 dollars, reflecting expectations for significantly stronger long term profit margins, despite slightly more conservative assumptions for revenue growth and valuation multiples. What's in the News Completed a share repurchase program totaling 10,342,722 shares, representing 6.76% of outstanding shares, for $309.28 million under the buyback announced on May 2, 2022 (Key Developments).Analysuppdatering • Nov 01
CC: Global Supply Agreements And Buybacks Will Drive Undervalued Shares Higher
Analysts have adjusted their price target for Chemours. They are maintaining the fair value estimate at $17.78, but have slightly increased the discount rate and are projecting a modest decrease in both expected revenue growth and profit margin based on recent outlook factors.Analysuppdatering • Oct 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours by $1.00, reflecting updated assumptions for modestly improved fair value and profit margin forecasts. What's in the News Chemours has entered into strategic agreements with SRF Limited to strengthen its global supply chain, enhance operational flexibility, and increase capacity for key materials such as fluoropolymers and fluoroelastomers (Key Developments).Analysuppdatering • Oct 03
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
Analysts have raised their price target for Chemours from $15.44 to $16.78, citing improved profit margins and slight increases in projected revenue growth as key factors for the update. What's in the News Chemours signed strategic agreements with SRF Limited to strengthen its global supply chain, increase operational flexibility, and secure fluoropolymer and fluoroelastomer capacity for multiple industries (Client Announcements).Analysuppdatering • Sep 17
Low GWP Refrigerants And Advanced Materials Will Drive Future Success
The modest increase in Chemours’ Consensus Analyst Price Target reflects slightly higher forward P/E expectations, while the discount rate remains stable, resulting in a revised fair value of $15.44. What's in the News Chemours signed strategic agreements with SRF Limited to enhance global supply chain, increase operational flexibility, and access capacity for fluoropolymers and fluoroelastomers, with no upfront capital investment required.Analysartikel • Sep 03
The Chemours Company (NYSE:CC) Held Back By Insufficient Growth Even After Shares Climb 33%
The Chemours Company ( NYSE:CC ) shares have continued their recent momentum with a 33% gain in the last month alone...Analysartikel • Jul 26
Is It Time To Consider Buying The Chemours Company (NYSE:CC)?
The Chemours Company ( NYSE:CC ), is not the largest company out there, but it saw a significant share price rise of...Analysartikel • Jul 04
The Chemours Company's (NYSE:CC) Price Is Right But Growth Is Lacking After Shares Rocket 30%
The Chemours Company ( NYSE:CC ) shares have had a really impressive month, gaining 30% after a shaky period...Analysartikel • Jun 29
Chemours (NYSE:CC) Has No Shortage Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • May 14
We Like The Quality Of Chemours' (NYSE:CC) Earnings
Despite posting healthy earnings, The Chemours Company's ( NYSE:CC ) stock has been quite weak. Along with the solid...Analysartikel • Apr 25
Is There An Opportunity With The Chemours Company's (NYSE:CC) 48% Undervaluation?
Key Insights The projected fair value for Chemours is US$23.71 based on 2 Stage Free Cash Flow to Equity Chemours is...Analysartikel • Mar 19
What Is The Chemours Company's (NYSE:CC) Share Price Doing?
The Chemours Company ( NYSE:CC ), might not be a large cap stock, but it saw significant share price movement during...Analysartikel • Mar 04
It's Down 27% But The Chemours Company (NYSE:CC) Could Be Riskier Than It Looks
To the annoyance of some shareholders, The Chemours Company ( NYSE:CC ) shares are down a considerable 27% in the last...Fördelning av intäkter och kostnader
Fördelning av intäkter och kostnader
Hur Chemours tjänar och spenderar pengar. Baserat på senast rapporterade resultat, på rullande tolvmånadersbasis.
Resultat- och intäktshistorik
| Datum | Intäkter | Intäkter | G+A Kostnader | FoU-kostnader |
|---|---|---|---|---|
| 31 Mar 26 | 5,821 | -410 | 528 | 107 |
| 31 Dec 25 | 5,808 | -386 | 504 | 108 |
| 30 Sep 25 | 5,837 | -338 | 598 | 107 |
| 30 Jun 25 | 5,850 | -430 | 627 | 111 |
| 31 Mar 25 | 5,788 | 10 | 603 | 108 |
| 31 Dec 24 | 5,782 | 69 | 618 | 109 |
| 30 Sep 24 | 5,835 | 63 | 557 | 109 |
| 30 Jun 24 | 5,814 | 106 | 505 | 107 |
| 31 Mar 24 | 5,904 | -329 | 538 | 110 |
| 31 Dec 23 | 6,078 | -253 | 1,286 | 108 |
| 30 Sep 23 | 6,004 | -317 | 567 | 112 |
| 30 Jun 23 | 6,294 | -87 | 624 | 117 |
| 31 Mar 23 | 6,566 | 489 | 689 | 114 |
| 31 Dec 22 | 6,831 | 578 | 705 | 118 |
| 30 Sep 22 | 7,031 | 908 | 688 | 117 |
| 30 Jun 22 | 6,933 | 881 | 670 | 111 |
| 31 Mar 22 | 6,673 | 746 | 560 | 113 |
| 31 Dec 21 | 6,345 | 608 | 583 | 107 |
| 30 Sep 21 | 6,108 | 394 | 582 | 104 |
| 30 Jun 21 | 5,662 | 256 | 572 | 100 |
| 31 Mar 21 | 5,100 | 215 | 539 | 93 |
| 31 Dec 20 | 4,969 | 219 | 526 | 93 |
| 30 Sep 20 | 4,984 | -117 | 463 | 86 |
| 30 Jun 20 | 5,140 | -117 | 472 | 83 |
| 31 Mar 20 | 5,455 | -46 | 508 | 82 |
| 31 Dec 19 | 5,526 | -52 | 536 | 80 |
| 30 Sep 19 | 5,637 | 407 | 600 | 82 |
| 30 Jun 19 | 5,876 | 606 | 610 | 83 |
| 31 Mar 19 | 6,284 | 792 | 647 | 84 |
| 31 Dec 18 | 6,638 | 995 | 630 | 82 |
| 30 Sep 18 | 6,749 | 1,081 | 603 | 80 |
| 30 Jun 18 | 6,705 | 1,013 | 597 | 80 |
| 31 Mar 18 | 6,476 | 893 | 578 | 82 |
| 31 Dec 17 | 6,183 | 746 | 592 | 81 |
| 30 Sep 17 | 5,930 | 288 | 582 | 82 |
| 30 Jun 17 | 5,744 | 285 | 605 | 81 |
| 31 Mar 17 | 5,540 | 106 | 616 | 76 |
| 31 Dec 16 | 5,400 | 7 | 591 | 81 |
| 30 Sep 16 | 5,438 | 151 | 605 | 89 |
| 30 Jun 16 | 5,526 | -82 | 615 | 87 |
| 31 Mar 16 | 5,651 | -82 | 598 | 97 |
| 31 Dec 15 | 5,717 | -90 | 632 | 97 |
| 30 Sep 15 | 5,906 | 75 | 634 | 101 |
| 30 Jun 15 | 6,052 | 211 | 653 | 116 |
Kvalitetsintäkter: CC är för närvarande olönsam.
Växande vinstmarginal: CC är för närvarande olönsam.
Fritt kassaflöde vs resultatanalys
Analys av tidigare vinsttillväxt
Resultatutveckling: CC är olönsam och förlusterna har ökat under de senaste 5 åren i en takt av 55.7% per år.
Accelererande tillväxt: Det går inte att jämföra CC s intäktstillväxt under det senaste året med dess 5-åriga genomsnitt eftersom det för närvarande är olönsamt
Resultat vs industri: CC är olönsam, vilket gör det svårt att jämföra det senaste årets vinsttillväxt med Chemicals branschen ( 3.5% ).
Avkastning på eget kapital
Hög ROE: CC har en negativ avkastning på eget kapital ( -189.81% ), eftersom det för närvarande är olönsamt.
Avkastning på tillgångar
Avkastning på sysselsatt kapital
Upptäck starka bolag som tidigare presterat bra
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/07 22:29 |
| Aktiekurs vid dagens slut | 2026/05/07 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
The Chemours Company bevakas av 19 analytiker. 9 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| null null | Alembic Global Advisors |
| David Coleman | Argus Research Company |
| Michael Leithead | Barclays |